Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1343535

registered interest
date	05/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to prepare for a covid-19 booster vaccination programme before winter 2021.
tabling member constituency	East Londonderry
tabling member printed	Mr Gregory Campbell
uin	27028
answer	answer is ministerial correction date of answer 08/07/2021 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) published interim advice on a potential COVID-19 booster vaccination programme on 30 June, which is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/jcvi-interim-advice-on-a-potential-coronavirus-covid-19-booster-vaccine-programme-for-winter-2021-to-2022" target="_blank">https://www.gov.uk/government/publications/jcvi-interim-advice-on-a-potential-coronavirus-covid-19-booster-vaccine-programme-for-winter-2021-to-2022</a></p><p>Final decisions on the timing and scope of the booster programme, as well as cohorts and eligibility, will be made later in the year, informed by further independent advice from the JCVI. NHS England and NHS Improvement are asking all local systems to develop detailed plans to ensure they are ready to deliver a booster programme from the start of September should this be required.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 08/07/2021 16:59:47 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	1409 label Biography information for Mr Gregory Campbell

1343538

registered interest
date	05/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus and Influenza: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether covid-19 booster vaccines and flu vaccines will be delivered (a) at the same time and (b) in pharmacies.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	27158
answer	answer is ministerial correction date of answer 13/07/2021 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) published interim advice on a potential COVID-19 booster vaccination programme on 30 June, which is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/jcvi-interim-advice-on-a-potential-coronavirus-covid-19-booster-vaccine-programme-for-winter-2021-to-2022" target="_blank">https://www.gov.uk/government/publications/jcvi-interim-advice-on-a-potential-coronavirus-covid-19-booster-vaccine-programme-for-winter-2021-to-2022</a></p><p>The JCVI recommends a two staged approach is recommended, with those in the first stage offered a booster and flu vaccine as soon as possible from September. Those in the second stage would be offered a booster vaccine as soon as practicable after stage one, with equal emphasis on deployment of the flu vaccine where eligible.</p><p>Final decisions on the timing and scope of the vaccine booster programme, as well as cohorts and eligibility, will be made later in the year, informed by further independent advice from the JCVI. This includes further data on the durability of protection from vaccines, data supplied by manufacturers and clinical trial data regarding COVID-19 vaccine and flu vaccine coadministration. On 1 July, NHS England and NHS Improvement wrote to primary care providers, including community pharmacies, outlining the JCVI’s interim advice to allow local planning to begin.</p><p> </p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 13/07/2021 16:05:46 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4131 label Biography information for Jim Shannon

1343576

registered interest
date	05/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will publish the covid-19 vaccine status of (a) people who die within 28 days of a positive covid-19 test and (b) new covid-19 infections.
tabling member constituency	Gravesham
tabling member printed	Adam Holloway
uin	27056
answer	answer is ministerial correction date of answer 13/07/2021 answer text <p>Public Health England (PHE) monitors the number of people who have been admitted to hospital and died from COVID-19 who have received one or two doses of the vaccine and will publish this data in due course. This includes the number of new cases of COVID-19 infection following vaccination.</p><p>PHE has not made a specific assessment of the potential effect of publishing information on the COVID-19 vaccine status of people who die within 28 days of a positive COVID-19 test and new COVID-19 infections on rates of vaccine uptake.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi grouped question UIN 27057 question first answered 13/07/2021 12:41:51 answering member 4113 label Biography information for Nadhim Zahawi previous answer version 12675 answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi answering member 4113 label Biography information for Nadhim Zahawi
tabling member	1522 label Biography information for Adam Holloway

1343331

registered interest
date	02/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans his Department has for a covid-19 vaccine booster campaign in autumn 2021.
tabling member constituency	Battersea
tabling member printed	Marsha De Cordova
uin	26161
answer	answer is ministerial correction date of answer 07/07/2021 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) published interim advice on a potential COVID-19 booster vaccination programme on 30 June 2021, which is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/jcvi-interim-advice-on-a-potential-coronavirus-covid-19-booster-vaccine-programme-for-winter-2021-to-2022" target="_blank">https://www.gov.uk/government/publications/jcvi-interim-advice-on-a-potential-coronavirus-covid-19-booster-vaccine-programme-for-winter-2021-to-2022</a></p><p>Final decisions on the timing and scope of the COVID-19 vaccine booster programme, as well as cohorts and eligibility, will not be made until later in the year, informed by further independent advice from the JCVI. NHS England and NHS Improvement are asking all local systems to develop detailed plans to ensure they are ready to deliver a booster programme from the start of September.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 07/07/2021 11:15:04 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4676 label Biography information for Marsha De Cordova

1343332

registered interest
date	02/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department plans to take to ensure long-term immune monitoring of people who have received a covid-19 vaccine booster.
tabling member constituency	Battersea
tabling member printed	Marsha De Cordova
uin	26162
answer	answer is ministerial correction date of answer 07/07/2021 answer text <p>The Joint Committee on Vaccination and Immunisation has made interim recommendations on the potential use of a COVID-19 vaccine booster. If the COVID-19 booster programme goes ahead, plans to evaluate the programme will be developed in due course.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 07/07/2021 11:12:21 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4676 label Biography information for Marsha De Cordova

1343333

registered interest
date	02/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department has taken to ensure long-term immune monitoring of people who have received different covid-19 vaccines for each dose.
tabling member constituency	Battersea
tabling member printed	Marsha De Cordova
uin	26163
answer	answer is ministerial correction date of answer 12/07/2021 answer text <p>The National Institute for Health Research has commissioned the National Immunisation Schedule Evaluation Consortium to undertake the Com-CoV trial. This trial is gathering data on the long-term immune response of using different COVID-19 vaccines for the first and second dose. Public Health England has also undertaken follow up on people given mixed schedules as part of routine care to monitor self-reported side effects and antibody response. The results will be published in due course. Current guidance recommends every effort should be made to complete the course with the same vaccine unless there are specific circumstances in which this is not appropriate.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 12/07/2021 08:41:38 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4676 label Biography information for Marsha De Cordova

1343339

registered interest
date	02/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 2 June 2021 to Question 6412 on Coronavirus: Vaccination, when his Department plans to publish the vaccine strategy.
tabling member constituency	Newton Abbot
tabling member printed	Anne Marie Morris
uin	26109
answer	answer is ministerial correction date of answer 15/07/2021 answer text <p>We are currently reviewing the proposed timetable for publication and we will provide more information in due course.</p><p> </p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 15/07/2021 15:35:38 answering member 4113 label Biography information for Nadhim Zahawi previous answer version 12355 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380
tabling member	4249 label Biography information for Anne Marie Morris

1343341

registered interest
date	02/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the validity of evidence that suggests that people who are immunocompromised or immunosuppressed may not receive the same level of protection from the covid-19 vaccines as the general population.
tabling member constituency	Newton Abbot
tabling member printed	Anne Marie Morris
uin	26110
answer	answer is ministerial correction date of answer 07/07/2021 answer text <p>Data from the Virus Watch study suggests a modestly reduced antibody response after one dose among individuals with immunosuppression, including those on immunosuppressive therapy. However, as this is not a direct measure of protection it is too soon to determine the impact on clinical disease or whether this remains after a complete course of vaccination.</p><p>As part of the COVID-19 Immunity National Core Study, UK Research and Innovation is providing £1.8 million towards the OCTAVE study. This study will examine the effectiveness of COVID-19 vaccines in clinically at-risk groups including patients with certain immunosuppressed conditions.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 07/07/2021 11:19:52 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4249 label Biography information for Anne Marie Morris

1343019

registered interest
date	01/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what research is being carried out to improve the level of antibodies in clinically extremely vulnerable people who have had two doses of the covid-19 vaccine but, as a result of their condition or medication, might be expected to respond poorly to the vaccination.
tabling member constituency	Hemel Hempstead
tabling member printed	Sir Mike Penning
uin	25754
answer	answer is ministerial correction date of answer 08/07/2021 answer text <p>UK Research and Innovation (UKRI) is providing £4 million towards the OCTAVE study to examine the effectiveness of COVID-19 vaccines in clinically at-risk groups, including patients with certain immunosuppressed conditions. UKRI has allocated a further £3 million towards a research call to support projects examining the nature and quality of COVID-19 vaccine responses and the mechanisms of immune failure that lead to either COVID-19 re-infection or vaccine breakthrough. This call is now closed and the results will be announced in due course.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 08/07/2021 17:02:02 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	1528 label Biography information for Sir Mike Penning

1343020

registered interest
date	01/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to monitor the level of antibodies in clinically extremely vulnerable people who have had two doses of the covid-19 vaccine but, as a result of their condition or medication, might be expected to respond poorly to the vaccination.
tabling member constituency	Hemel Hempstead
tabling member printed	Sir Mike Penning
uin	25755
answer	answer is ministerial correction date of answer 08/07/2021 answer text <p>Public Health England has been monitoring the effectiveness of vaccinations in clinical risk groups which will include those with immunosuppression.</p><p>From the evaluation of the vaccine programme, the data shows that completion of the two dose schedule correlates well with protection from both disease and severe outcomes, including hospitalisation and death.</p><p>Virus Watch data, supported by the United Kingdom Research and Innovation and National Institute for Health Research COVID-19 rapid response initiative and the antibody testing team in NHS Test and Trace, provided information regarding patients antibodies which included immunocompromised patients as part of their cohort. This suggests some protection against COVID-19, but is only one measure of protection and does not look at cellular immunity which is important in terms of long-term immunity.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 08/07/2021 17:04:32 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	1528 label Biography information for Sir Mike Penning